|
|
| February 12, 2008 |
Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech |
| December 20, 2007 |
Altor BioScience Advances Clinical Trial for Targeted Cancer Therapeutic, ALT-801 |
| July 25, 2006 |
Altor BioScience Awarded Phase II SBIR Grant for Anti-Cancer Antibody Manufacture in Transgenic Plants |
| March 13, 2006 |
Altor BioScience Introduces STAR(TM) Multimer Reagents to Measure Disease-Specific Antigen Presentation |
| July 21, 2005 |
Altor BioScience Awarded SBIR Grant for Manufacturing Therapeutic Antibodies in Transgenic Plants |
| January 19, 2005 |
Altor BioScience Establishes Collaboration with Leading MGH Investigator to Develop TCR-based Agents to Detect and Treat HIV and HCV Infection |
| September 20, 2004 |
Altor Bioscience Receives Phase II SBIR Grant for Next-Generation Cancer Therapeutics |
| March 29, 2004 |
Altor BioScience Reports Advancements in its Soluble T-cell Receptor-Based Technology Programs |
| November 11, 2003 |
Altor Bioscience Reports Pre-Clinical Results Supporting Utility of Soluble T-Cell Receptor Fusions for Cancer Immunotherapy |
| September 26, 2003 |
Altor Bioscience Awarded NIH Grant to Expand Screening Program to Identify Orally Available Drugs to Treat Multiple Sclerosis |
| June 1, 2003 |
Altor Bioscience Receives SBIR Grant from NIAID for Development of Anti-Viral TCR Therapeutics |
| March 18, 2003 |
Altor Bioscience Issued New U.S. Patent for Innovative T-cell Receptor Technology |
Back
© Altor BioScience Corporation, 2007
|
|
